fosfomycin 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definition	Drug id	CAS RN
antibiotics, produced by Streptomyces strains	1243	23155-02-4

Description:

Molecule	Description
Molfile Inchi Smiles Synonyms: fosfomycin trometamol fosfomycin fosfomycin tromethamine	An antibiotic produced by Streptomyces fradiae. Molecular weight: 138.06 Formula: C3H7O4P CLOGP: -0.03 LIPINSKI: 0 HAC: 4 HDO: 2 TPSA: 70.06 ALOGS: -0.47 ROTB: 1 Status: OFP Legend: OFP - off patent OFM - off market ONP - on patent

Molecule

Description

Molfile Inchi Smiles

Synonyms:

fosfomycin trometamol
fosfomycin
fosfomycin tromethamine

An antibiotic produced by Streptomyces fradiae.

Molecular weight: 138.06
Formula: C3H7O4P
CLOGP: -0.03
LIPINSKI: 0
HAC: 4
HDO: 2
TPSA: 70.06
ALOGS: -0.47
ROTB: 1

Status: OFP

Legend:
OFP - off patent
OFM - off market
ONP - on patent

Drug dosage:

Dose	Unit	Route
3	g	O
8	g	P

ADMET properties:

Property	Value	Reference
BDDCS (Biopharmaceutical Drug Disposition Classification System)	3	Benet LZ, Broccatelli F, Oprea TI
S (Water solubility)	50 mg/mL	Benet LZ, Broccatelli F, Oprea TI
EoM (Fraction excreted unchanged in urine)	82 %	Benet LZ, Broccatelli F, Oprea TI
MRTD (Maximum Recommended Therapeutic Daily Dose)	192.90 µM/kg/day	Contrera JF, Matthews EJ, Kruhlak NL, Benz RD
BA (Bioavailability)	31 %	Kim MT, Sedykh A, Chakravarti SK, Saiakhov RD, Zhu H
Vd (Volume of distribution)	0.32 L/kg	Lombardo F, Berellini G, Obach RS
CL (Clearance)	2 mL/min/kg	Lombardo F, Berellini G, Obach RS
fu (Fraction unbound in plasma)	1 %	Lombardo F, Berellini G, Obach RS
t_half (Half-life)	1.90 hours	Lombardo F, Berellini G, Obach RS

Approvals:

Date	Agency	Company	Orphan
Dec. 19, 1996	FDA	ZAMBON SPA

FDA Adverse Event Reporting System (Female)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Cardiospasm	226.80	26.54	51	7323	1856	63479792
Palmoplantar keratoderma	224.20	26.54	51	7323	1956	63479692
Pruritus genital	210.03	26.54	51	7323	2603	63479045
Sleep terror	209.53	26.54	51	7323	2629	63479019
Atrial tachycardia	190.97	26.54	52	7322	4188	63477460
Carotid artery occlusion	181.18	26.54	51	7323	4643	63477005
Tension headache	176.15	26.54	51	7323	5135	63476513
Anosmia	170.45	26.54	53	7321	6807	63474841
Facial pain	148.01	26.54	53	7321	10508	63471140
Immunisation	136.93	26.54	31	7343	1162	63480486
Pain of skin	135.69	26.54	51	7323	11583	63470065
Subarachnoid haemorrhage	125.53	26.54	51	7323	14232	63467416
Ventricular tachycardia	115.31	26.54	53	7321	19926	63461722
Vasculitis	113.60	26.54	51	7323	18158	63463490
Eye pruritus	112.38	26.54	51	7323	18620	63463028
Muscle twitching	109.84	26.54	51	7323	19617	63462031
Blindness	108.09	26.54	52	7322	21647	63460001
Diplopia	100.74	26.54	51	7323	23677	63457971
Lip swelling	95.90	26.54	54	7320	31009	63450639
Hallucination	87.98	26.54	63	7311	54754	63426894
Transient ischaemic attack	83.63	26.54	53	7321	37700	63443948
Tinnitus	78.87	26.54	50	7324	35578	63446070
Disturbance in attention	78.13	26.54	51	7323	38138	63443510
Angioedema	72.12	26.54	53	7321	47912	63433736
Dry skin	70.46	26.54	56	7318	56831	63424817
Rash papular	67.36	26.54	34	7340	15668	63465980
Cognitive disorder	67.11	26.54	54	7320	55761	63425887
Amnesia	65.18	26.54	53	7321	55532	63426116
Intentional product misuse	60.94	26.54	53	7321	60864	63420784
Heart rate increased	54.91	26.54	61	7313	94177	63387471
COVID-19	52.25	26.54	65	7309	113038	63368610
Tachycardia	51.57	26.54	66	7308	118090	63363558
Migraine	48.71	26.54	60	7314	103286	63378362
Blood glucose increased	48.42	26.54	54	7320	83702	63397946
Feeling abnormal	48.38	26.54	72	7302	148320	63333328
Drug reaction with eosinophilia and systemic symptoms	47.74	26.54	36	7338	33800	63447848
Visual impairment	44.67	26.54	52	7322	84394	63397254
Dehydration	42.65	26.54	74	7300	173280	63308368
Hyperhidrosis	42.03	26.54	57	7317	107779	63373869
Myocardial infarction	39.23	26.54	53	7321	99840	63381808
Palpitations	38.59	26.54	56	7318	112714	63368934
Muscular weakness	37.92	26.54	58	7316	122295	63359353
Memory impairment	34.54	26.54	51	7323	104207	63377441
Pericarditis	33.43	26.54	57	7317	131522	63350126
Stevens-Johnson syndrome	29.67	26.54	24	7350	24926	63456722
Respiratory alkalosis	28.45	26.54	11	7363	2690	63478958
Malaise	28.26	26.54	109	7265	415845	63065803
Pruritus	28.14	26.54	99	7275	361354	63120294
Umbilical cord around neck	27.32	26.54	6	7368	195	63481453
Mechanical urticaria	26.95	26.54	7	7367	469	63481179
Anxiety	26.73	26.54	70	7304	217471	63264177

FDA Adverse Event Reporting System (Male)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Cardiospasm	295.85	54.53	66	6034	1522	34949309
Palmoplantar keratoderma	276.99	54.53	65	6035	1888	34948943
Pruritus genital	264.04	54.53	64	6036	2140	34948691
Sleep terror	260.83	54.53	64	6036	2254	34948577
Tension headache	248.37	54.53	65	6035	2977	34947854
Atrial tachycardia	241.37	54.53	66	6034	3579	34947252
Facial pain	235.69	54.53	65	6035	3639	34947192
Carotid artery occlusion	235.12	54.53	65	6035	3672	34947159
Anosmia	234.91	54.53	66	6034	3958	34946873
Immunisation	201.88	54.53	45	6055	1032	34949799
Pain of skin	199.47	54.53	64	6036	6045	34944786
Eye pruritus	198.45	54.53	67	6033	7422	34943409
Pericarditis	169.59	54.53	67	6033	11578	34939253
Vasculitis	168.04	54.53	66	6034	11230	34939601
Muscle twitching	166.77	54.53	64	6036	10234	34940597
Lip swelling	164.83	54.53	72	6028	16008	34934823
Subarachnoid haemorrhage	160.87	54.53	66	6034	12569	34938262
Blindness	146.79	54.53	65	6035	14921	34935910
Migraine	140.30	54.53	66	6034	17412	34933419
Diplopia	136.42	54.53	64	6036	16779	34934052
Tinnitus	128.53	54.53	65	6035	20053	34930778
Rash papular	128.47	54.53	53	6047	10225	34940606
Disturbance in attention	126.56	54.53	70	6030	25875	34924956
Pathogen resistance	125.70	54.53	51	6049	9431	34941400
Dry skin	119.53	54.53	72	6028	31215	34919616
Amnesia	114.24	54.53	66	6034	26497	34924334
Alopecia	114.11	54.53	64	6036	24291	34926540
Ventricular tachycardia	111.54	54.53	65	6035	26514	34924317
Transient ischaemic attack	109.24	54.53	65	6035	27548	34923283
Cognitive disorder	106.94	54.53	65	6035	28628	34922203
Visual impairment	100.90	54.53	68	6032	35734	34915097
Angioedema	93.57	54.53	66	6034	37308	34913523
Palpitations	89.56	54.53	66	6034	39920	34910911
Memory impairment	82.69	54.53	65	6035	43253	34907578
Intentional product misuse	79.73	54.53	65	6035	45546	34905285
Hallucination	76.87	54.53	67	6033	51431	34899400
Heart rate increased	76.74	54.53	64	6036	46279	34904552
COVID-19	67.27	54.53	75	6025	77475	34873356
Abdominal discomfort	64.55	54.53	65	6035	59770	34891061
Feeling abnormal	63.33	54.53	66	6034	63169	34887662
Blood glucose increased	58.66	54.53	65	6035	66653	34884178
Muscular weakness	57.28	54.53	67	6033	72830	34878001

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Cardiospasm	501.39	28.82	114	12461	3187	79728626
Palmoplantar keratoderma	482.68	28.82	113	12462	3603	79728210
Sleep terror	457.14	28.82	112	12463	4346	79727467
Pruritus genital	456.44	28.82	112	12463	4374	79727439
Atrial tachycardia	418.78	28.82	115	12460	7018	79724795
Tension headache	408.31	28.82	113	12462	7098	79724715
Carotid artery occlusion	401.75	28.82	113	12462	7534	79724279
Anosmia	398.75	28.82	116	12459	8728	79723085
Facial pain	356.47	28.82	115	12460	12235	79719578
Pain of skin	325.76	28.82	112	12463	14501	79717312
Immunisation	324.52	28.82	74	12501	2093	79729720
Eye pruritus	299.09	28.82	115	12460	20455	79711358
Subarachnoid haemorrhage	276.35	28.82	114	12461	24351	79707462
Vasculitis	273.52	28.82	114	12461	24988	79706825
Muscle twitching	268.27	28.82	112	12463	24652	79707161
Blindness	260.03	28.82	114	12461	28269	79703544
Lip swelling	243.63	28.82	122	12453	40789	79691024
Diplopia	235.90	28.82	112	12463	33354	79698459
Ventricular tachycardia	220.51	28.82	115	12460	41820	79689993
Tinnitus	206.11	28.82	112	12463	44221	79687592
Disturbance in attention	205.21	28.82	117	12458	50684	79681129
Transient ischaemic attack	195.93	28.82	115	12460	52580	79679233
Dry skin	190.78	28.82	124	12451	67871	79663942
Rash papular	181.37	28.82	82	12493	21834	79709979
Amnesia	179.37	28.82	116	12459	62941	79668872
Hallucination	169.26	28.82	126	12449	85619	79646194
Cognitive disorder	168.45	28.82	116	12459	69810	79662003
Angioedema	157.41	28.82	115	12460	75920	79655893
Migraine	155.99	28.82	121	12454	87372	79644441
Visual impairment	139.93	28.82	116	12459	92015	79639798
Pericarditis	137.42	28.82	121	12454	104115	79627698
Intentional product misuse	134.60	28.82	115	12460	95050	79636763
Pathogen resistance	126.10	28.82	56	12519	14286	79717527
Heart rate increased	124.09	28.82	122	12453	120602	79611211
COVID-19	120.45	28.82	136	12439	157538	79574275
Blood glucose increased	117.81	28.82	116	12459	114859	79616954
Memory impairment	114.98	28.82	113	12462	111621	79620192
Palpitations	112.00	28.82	118	12457	126492	79605321
Feeling abnormal	104.41	28.82	127	12448	159072	79572741
Tachycardia	97.89	28.82	130	12445	177638	79554175
Muscular weakness	95.43	28.82	122	12453	160607	79571206
Hyperhidrosis	88.37	28.82	114	12461	151378	79580435
Myocardial infarction	75.40	28.82	117	12458	184012	79547801
Dehydration	67.96	28.82	132	12443	248055	79483758
Drug resistance	63.70	28.82	53	12522	42160	79689653
Alopecia	60.84	28.82	121	12454	231234	79500579
Chest pain	59.61	28.82	135	12440	282169	79449644
Insomnia	58.30	28.82	123	12452	245047	79486766
Abdominal pain upper	57.58	28.82	116	12459	223703	79508110
Anxiety	57.16	28.82	123	12452	248389	79483424
Pruritus	53.70	28.82	160	12415	394488	79337325
Intentional product use issue	53.17	28.82	90	12485	152022	79579791
Peripheral swelling	51.51	28.82	124	12451	269493	79462320
Back pain	50.90	28.82	133	12442	304047	79427766
Abdominal discomfort	50.81	28.82	118	12457	250609	79481204
Malaise	49.09	28.82	179	12396	489690	79242123
Death	41.12	28.82	19	12556	566495	79165318
Adverse drug reaction	38.71	28.82	50	12525	66342	79665471
Toxicity to various agents	32.37	28.82	13	12562	421527	79310286
Conductive deafness	29.44	28.82	7	12568	238	79731575
Drug hypersensitivity	28.84	28.82	6	12569	298910	79432903

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

Source	Code	Description
ATC	J01XX01	ANTIINFECTIVES FOR SYSTEMIC USE ANTIBACTERIALS FOR SYSTEMIC USE OTHER ANTIBACTERIALS Other antibacterials
ATC	S02AA17	SENSORY ORGANS OTOLOGICALS ANTIINFECTIVES Antiinfectives
MeSH PA	D000900	Anti-Bacterial Agents
MeSH PA	D000890	Anti-Infective Agents
CHEBI has role	CHEBI:33281	antibiotics
CHEBI has role	CHEBI:78379	EC 2.5.1.7 inhibitors

Drug Use | Suggest Off label Use Form| |View source of the data|

Disease	Relation	SNOMED_ID	DOID
Urinary tract infectious disease	indication	68566005
Escherichia coli urinary tract infection	indication	301011002
Enterococcus Urinary Tract Infection	indication
Kidney disease	contraindication	90708001	DOID:557
Pseudomembranous enterocolitis	contraindication	397683000

🐶 Veterinary Drug Use

None

🐶 Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation level	Dissociation constant	Type (acidic/basic)
pKa1	0.54	acidic
pKa2	5.59	acidic

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

Target	Class	UniProt	Action	Type	Activity value (-log[M])	Bioact source	MoA source
UDP-N-acetylglucosamine 1-carboxyvinyltransferase	Enzyme	MURA_ECOLI	INHIBITOR	IC50	7	CHEMBL	CHEMBL
UDP-N-acetylglucosamine 1-carboxyvinyltransferase 1	Enzyme	MURA1_ENTFA				WOMBAT-PK
UDP-N-acetylglucosamine 1-carboxyvinyltransferase 2	Enzyme	MURA2_ENTFA				WOMBAT-PK
UDP-N-acetylglucosamine 1-carboxyvinyltransferase	Enzyme	MURA_PSEAE		IC50	4.98	CHEMBL

External reference:

ID	Source
4024047	VUID
N0000022052	NUI
D00925	KEGG_DRUG
78964-85-9	SECONDARY_CAS_RN
4021007	VANDF
4024047	VANDF
C0016610	UMLSCUI
CHEBI:62419	CHEBI
FCN	PDB_CHEM_ID
CHEMBL1757	ChEMBL_ID
DB00828	DRUGBANK_ID
CHEMBL1200331	ChEMBL_ID
D005578	MESH_DESCRIPTOR_UI
446987	PUBCHEM_CID
3014	INN_ID
10813	IUPHAR_LIGAND_ID
2N81MY12TE	UNII
142135	RXNORM
29490	MMSL
340066	MMSL
4765	MMSL
d04106	MMSL
004467	NDDF
004468	NDDF
108720006	SNOMEDCT_US
108721005	SNOMEDCT_US
372534005	SNOMEDCT_US

Pharmaceutical products:

Product	Category	Ingredients	NDC	Form	Quantity	Route	Marketing	Label
Monurol	HUMAN PRESCRIPTION DRUG LABEL	1	0456-4300	POWDER	3 g	ORAL	NDA	23 sections
Monurol	HUMAN PRESCRIPTION DRUG LABEL	1	0456-4300	POWDER	3 g	ORAL	NDA	23 sections
FOSFOMYCIN TROMETHAMINE	HUMAN PRESCRIPTION DRUG LABEL	1	50090-5826	POWDER	3 g	ORAL	ANDA	20 sections
FOSFOMYCIN TROMETHAMINE	HUMAN PRESCRIPTION DRUG LABEL	1	50090-5826	POWDER	3 g	ORAL	ANDA	20 sections
Fosfomycin Tromethamine	Human Prescription Drug Label	1	50090-6130	GRANULE, FOR SOLUTION	3 g	ORAL	ANDA	21 sections
Fosfomycin Tromethamine	HUMAN PRESCRIPTION DRUG LABEL	1	63629-9470	GRANULE, FOR SOLUTION	3 g	ORAL	ANDA	21 sections
Fosfomycin Tromethamine	Human Prescription Drug Label	1	67877-749	GRANULE, FOR SOLUTION	3 g	ORAL	ANDA	21 sections
Fosfomycin Tromethamine	Human Prescription Drug Label	1	67877-749	GRANULE, FOR SOLUTION	3 g	ORAL	ANDA	21 sections
FOSFOMYCIN TROMETHAMINE	HUMAN PRESCRIPTION DRUG LABEL	1	69097-579	GRANULE, FOR SOLUTION	3 g	ORAL	ANDA	18 sections
FOSFOMYCIN TROMETHAMINE	HUMAN PRESCRIPTION DRUG LABEL	1	70700-268	POWDER	3 g	ORAL	ANDA	20 sections
FOSFOMYCIN TROMETHAMINE	HUMAN PRESCRIPTION DRUG LABEL	1	70700-268	POWDER	3 g	ORAL	ANDA	20 sections
Fosfomycin Tromethamine	HUMAN PRESCRIPTION DRUG LABEL	1	82036-4274	POWDER	3 g	ORAL	NDA authorized generic	22 sections
Fosfomycin Tromethamine	HUMAN PRESCRIPTION DRUG LABEL	1	82036-4274	POWDER	3 g	ORAL	NDA authorized generic	22 sections